Numerous reported data support the idea that Brain Derived Neurotrophic Factor (BDNF) is critically involved in both depression and comorbid pain. The possible direct effect of BDNF on pain mechanisms was assessed here and compared with behavioral/neurobiological features of neuropathic pain caused by chronic constriction injury to the sciatic nerve (CCI-SN). Sprague-Dawley male rats were either injected intrathecally with BDNF (3.0 ng i.t.) or subjected to unilateral CCI-SN. Their respective responses to anti-hyperalgesic drugs were assessed using the Randall-Selitto test and both immunohistochemical and RT-qPCR approaches were used to investigate molecular/cellular mechanisms underlying hyperalgesia in both models. Long lasting hyperalgesia and allodynia were induced by i.t. BDNF in intact healthy rats like those found after CCI-SN. Acute treatment with the BDNF-TrkB receptor antagonist cyclotraxin B completely prevented i.t. BDNF-induced hyperalgesia and partially reversed this symptom in both BDNF-pretreated and CCI-SN lesioned rats. Acute administration of the anticonvulsant pregabalin, the NMDA receptor antagonist ketamine, the opioid analgesics morphine and tapentadol or the antidepressant agomelatine also transiently reversed hyperalgesia in both i.t. BDNF injected-and CCI-SN lesioned-rats. Marked induction of microglia activation markers (OX42, Iba1, P-p38), proinflammatory cytokine IL-6, NMDA receptor subunit NR2B and BDNF was found in spinal cord and/or dorsal root ganglia of CCI-SN rats. A long lasting spinal BDNF overexpression was also observed in BDNF i.t. rats, indicating an autocrine self-induction, with downstream long lasting TrkB-mediated neuropathic-like pain. Accordingly, TrkB blockade appeared as a relevant approach to alleviate not only i.t. BDNF-but also nerve lesion-evoked neuropathic pain.
Respective pharmacological features of neuropathic-like pain evoked by intrathecal BDNF versus sciatic nerve ligation in rats

-Introduction
Comorbidity between depression and chronic neuropathic pain has been repeatedly reported in the relevant literature, suggesting the existence of at least some common underlying mechanisms (Chopra and Arora, 2014) . In support with this inference, first line treatment of chronic neuropathic pain is based on effective antidepressant drugs, especially tricyclics and mixed inhibitors of noradrenaline and serotonin reuptake (Finnerup et al., 2015) . However, whether antidepressant drugs really act through a facilitation of monoaminergic neurotransmission to reduce neuropathic pain is still a matter of debate.
Indeed, these drugs can also affect neuroinflammatory processes, interact directly with voltage-dependent cation channels involved in the transmission of nociceptive signals and block some pain-related receptors, and these actions might also contribute to their antineuropathic pain properties (Vranken, 2012) .
Among endogenous molecules involved in both depression and antidepressants' action on the one hand, and chronic pain on the other hand, the neurotrophin Brain Derived Neurotrophic Factor (BDNF) seems to play cardinal roles Autry and Monteggia, 2012) . A large consensus has led to the conclusion that depression is associated with BDNF downregulation in brain areas such as the hippocampus and the frontal cortex (Cai et al., 2015) , and it has been recently proposed that depression-like behavior caused by some pro-inflammatory cytokines might be underlain by their capacity to downregulate hippocampal BDNF (Calabrese et al., 2014) . Conversely, antidepressants, including the atypical antidepressant ketamine, have been shown to enhance BDNF production, or even transactivate the BDNF-TrkB (tropomyosin receptor kinase B) receptor, thereby counteracting depression-associated BDNF-TrkB downregulation (Lindholm and Castrén, 2014) . That antidepressants could act through supraspinal BDNF-TrkB activation is supported by data showing that direct intracerebral administration of BDNF itself exerts antidepressant-like effects in validated rodent models of depression (Shirayama et al., 2002) .
However, it would be irrelevant to infer that an upregulation of BDNF always contributes to an antidepressant action because direct injection of BDNF into the ventral tegmental area was found to cause depression-like behavior, whereas BDNF signaling blockade in the nucleus accumbens produced antidepressant-like effects (Berton et al., 2006) .
Regarding pain, the role of BDNF is also a matter of debate because both antinociceptive (Cejas et al., 2000; Lever et al., 2003) and pronociceptive (Groth and Aanonsen, 2002; Constandil et al., 2011 Constandil et al., , 2012 effects have been reported after direct administration of this neurotrophin intracerebroventricularly or intrathecally (i.t.) in rodents. Furthermore, inflammatory but not neuropathic pain seems to implicate BDNF (Zhao et al., 2006) , which may suggest that the anti-neuropathic pain effect of antidepressants would not involve this neurotrophin, in line with a recent report showing that the antihyperalgesic effect of amitriptyline was not associated with any change of spinal BDNF levels in CCI-SN rats (Vanelderen et al., 2013) .
All these rather heterogeneous data led us to reinvestigate the effects of direct administration of BDNF at spinal level for a thorough comparison with authentic neuropathic pain symptoms caused by unilateral chronic constriction injury to the sciatic nerve (CCI-SN) in rats. In particular, drugs known to be effective to alleviate neuropathic pain, especially antidepressants, anticonvulsants and opioids (Finnerup et al., 2015) were tested in both BDNF-treated and CCI-SN-lesioned rats. In addition, quantitative RT-PCR and immunohistochemistry were used to investigate whether microglial and neuroplasticity markers were affected in BDNF i.t. rats like that previously described in CCI-SN rats (Latrémolière et al., 2008) 
Surgery
Chronic constriction injury to the sciatic nerve
Rats were anesthetized with sodium pentobarbital (50 mg/kg, i.p.), and unilateral CCI-SN was made according to the procedure of Bennett and Xie (1988) . Briefly, the right common sciatic nerve was exposed at mid-thigh level and freed from adhering tissue allowing the disposition of four ligatures (5.0 silk suture) tied loosely with 1 mm spacing. Sham rats underwent the same surgery without ligatures. Muscle and skin were then closed in layers with silk suture (4.0) and rats were allowed to recover for one week in their home cage.
Intrathecal injection
Rats were slightly anesthetized using isoflurane (3% in air) and injected into the subarachnoid space between L5 and L6 vertebrae using a 26 G needle connected to a Hamilton syringe (Mestre et al., 1994) . Each rat received 12 µL of vehicle (0.9% NaCl) or BDNF solution ("BDNF i.t.", Peprotech, 92200 Neuilly, France). The dose of BDNF (3.0 ng/12 µL of saline) was selected from previous studies (Groth and Aanonsen, 2002; Constandil et al., 2011 Constandil et al., , 2012 .
Behavioral tests
All tests were performed by an experienced person blind to treatment groups.
Paw pressure test
Mechanical nociceptive thresholds, expressed as grams (g), were measured using an Ugo
Basile algesimeter (Bioseb, 92370 Chaville, France) according to Randall and Selitto (1957) .
Pressure thresholds to trigger paw withdrawal then vocalization (Kayser et al., 2010) were determined on the day before nerve injury or intrathecal injection (basal values) and then on day 15 after surgery for CCI-SN rats or on day 10 after i.t. injection for BDNF i.t. rats, when hypersensitivity to mechanical stimulation had fully developed (see Results).
Pharmacological treatments started immediately thereafter, and thresholds were determined at regular time intervals (30 or 60 min) after drug administration. Only animals showing clear-cut mechanical hypersensitivity (approximately 60% of CCI-SN rats and 80% of BDNF i.t. rats), with a reduction of nociceptive thresholds of at least 30% compared to shamoperated/vehicle i.t. rats, were used for pharmacological studies.
von Frey filaments test
Each rat was first habituated for two hours in a quiet room, and mechanical sensitivity was then determined with a graded series of eight von Frey filaments (4, 6, 8, 10, 12, 15, 26 and 60 g; Latrémolière et al., 2008) applied to the lateral plantar surface of hindpaw (ipsilateral to CCI-SN, bilaterally in BDNF i.t. rats). The up-down procedure of Chaplan et al. (1994) was used to determine the pressure threshold to trigger hindpaw withdrawal. When no response was observed, the force of the thickest filament (60 g) was arbitrarily assigned as the "cutoff" value (see Latrémolière et al., 2008) .
Pharmacological treatments
Cyclotraxin B (Bio S&T, Montreal, Canada), pregabalin (Sequoia, Pangbourne, UK), morphine (Pharmacie Centrale des Hôpitaux de Paris, France), tapentadol (Grünenthal, Aachen, Germany), agomelatine (Servier, Suresnes, France), ketamine, duloxetine and amitriptyline (Sigma-Aldrich, Saint-Quentin Fallavier, France), clonazepam (Roche, Basel, Switzerland)
were administered using routes and doses previously reported to be active at their respective molecular targets (Cazorla et al., 2010; de Bodinat et al., 2010; Lau et al., 2013; Michot et al., 2013; M'Dahoma et al., 2014) . Drugs were injected i.p. in a volume of 1 mL/kg, except morphine which was injected subcutaneously (1 mL/kg, s.c.). Cyclotraxin B, morphine, tapentadol, pregabalin, ketamine and amitriptyline were dissolved in 0.9 % NaCl.
Agomelatine and duloxetine were dissolved in 1% hydroxyethylcellulose (HEC) in water, and clonazepam in ethanol:water (50:50). Control animals received respective vehicles using the same routes of administration.
Immunohistochemistry
Stroking stimulation
Previous studies showed that gentle (non noxious) mechanical stimulation of hindpaw allowed immunocytochemical visualization of neuronal sensitization underlying hyperalgesia/allodynia-like responses in rats (Kayser et al., 2010) . This protocol was used here to look for possible neuronal sensitization at spinal level in rats that had been i.t.
injected with BDNF 10 days before. Briefly, gentle touch stimulus with a paint brush was applied once every 10 sec for 10 min to the right hindpaw. This touch stimulus feels like a stroke in human volunteers and does not elicit a flexion reflex in naïve healthy rats. Such stroking stimulation was performed 24 h before deep anesthesia and perfusion for immunohistochemical procedure (2.5.2.).
Immunohistochemical procedure
Fifteen days after CCI-SN and 11 days after i.t. BDNF, rats were deeply anesthetized with pentobarbital (50 mg/kg i.p.) and perfused intracardially with a heparin (25 IU/ml)-saline solution, followed by 0.12 M phosphate buffered saline (PBS, pH 7.4) containing 4% paraformaldehyde, 0.1% glutaraldehyde and 0.05% picric acid, and finally by 20% sucrose solution. The spinal cord was removed and cryoprotected in 20% sucrose solution overnight.
Coronal floating sections (30 µm thick) of the lumbar enlargement were collected and then processed in parallel, with the same reagents, under the very same conditions (see Kayser et al., 2010) . To label phospho-p38 (P-p38), the activated form of p38 MAP kinase (Jin et al., 2003) , sections were incubated with the primary antibody (rabbit anti-P-p38, 1/3,000, Cell (Schmittgen and Livak, 2008 ) was used to analyze the relative changes in specific mRNA levels. The Student's t test was used to compare immunohistochemical and RT-qPCR data in treated versus control group when only 2 groups were analysed. A 1-way ANOVA followed by a Newman Keuls test was used when comparison was made between 3 or more groups. In all cases, significance level was set at P < 0.05.
Results
Time course development of mechanical hyperalgesia and allodynia in CCI-SN
and BDNF i.t. rats.
CCI-SN induced a progressively developing mechanical hyperalgesia at the ipsilateral hindpaw that reached its maximal intensity two weeks after surgery ( Fig. 1 A) . BDNF i.t. also induced mechanical hyperalgesia, but more rapidly than CCI-SN, since the maximal decrease in pressure threshold values determined with the Randall-Selitto test was reached as soon as one week post injection ( Fig. 1B ). As shown in figure 2, the intensity of mechanical hyperalgesia as assessed from maximal decreases in pressure threshold values to trigger hindpaw withdrawal (-33.9 %, P<0.001) and vocalization (-36.9%, P<0.01) in BDNF i.t. versus saline i.t. rats was similar to that found in CCI-SN versus sham-operated rats (-33.4%, P<0.05, and -35.8%, P<0.001, respectively). Furthermore, like that occurring after CCI-SN, mechanical hyperalgesia evoked by i.t. BDNF was a long lasting response which persisted for at least one month post-injection ( Fig. 1B) .
Von Frey filaments test showed that mechanical allodynia also developed after CCI-SN ( Fig.   1C ) and BDNF i.t. (Fig. 1D ). Indeed, allodynia was as pronounced and lasted for at least four weeks under either condition (Fig. 1C,1D ). However, maximal allodynia-like response was reached much earlier in BDNF i.t.-than in CCI-SN-rats ( Fig. 1D compared to Fig. 1C ).
Effects of various drugs on mechanical hyperalgesia in BDNF i.t. versus CCI-SNrats
Effects of antihyperalgesic drugs, pregabalin and ketamine
Two weeks after CCI-SN or 10 days after i.t. BDNF, acute treatment with pregabalin (30 mg/kg i.p.) significantly reduced hyperalgesia as shown by the return of pressure threshold values up to the range observed in naïve healthy rats subjected to the Randall-Selitto test ( Fig. 3A,3B ). Similar time courses of the drug effect were observed in both models, with complete reversal of hyperalgesia at 2-3 hours post-treatment, followed by its progressive reappearance down to pre-treatment threshold values 24 h after pregabalin administration ( Fig. 3A,3B ). Ketamine (50 mg/kg i.p.) also reduced hyperalgesia in both models (Fig. 3C,3D ), but its effects were less pronounced and of shorter duration than pregabalin ( Fig. 3C,3D ).
Effects of opioid receptor agonists, morphine and tapentadol
In both CCI-SN-and BDNF i.t.-rats, acute treatment with morphine (3 mg/kg s.c., Fig. 4A ,4B) and tapentadol (10 mg/kg i.p., Fig. 4C ,4D) also reduced mechanical hyperalgesia as shown by significant increases in pressure threshold values to trigger vocalization in the Randall-Selitto test. Complete reversal of hyperalgesia was observed up to one hour after morphine administration, but this effect vanished rapidly and was no longer significant one hour later ( Fig. 4A,4B ). As shown in figure 4C ,4D, the effect of tapentadol was even more transient since it had completely disappeared 90 min after the drug administration.
Effects of agomelatine, amitriptyline, duloxetine and clonazepam
As shown in figure 
Effects of TrkB receptor blockade by cyclotraxin B
Prevention by cyclotraxin B of BDNF i.t.-induced hyperalgesia
When administered twice, 15 min before and 15 min after i.t. injection of BDNF, cyclotraxin B, at an effective dose (20 mg/kg i.p.) to block BDNF-TrkB receptor in the central nervous system (Cazorla et al., 2010) , prevented the hyperalgesic-like effect normally induced by the trophic factor. As shown in figure 6 , the BDNF-induced decrease in pressure threshold values to trigger hindpaw withdrawal ( Fig. 6A ) and vocalization ( Fig. 6B ) in the Randall-Selitto test did not occur for at least one week after cyclotraxin-B administration. On its own, cyclotraxin B did not significantly affect pressure threshold values in naïve rats (not shown).
Reversal by cyclotraxin B of CCI-SN-and BDNF i.t.-induced hyperalgesia
When injected two weeks after surgery in CCI-SN rats, cyclotraxin B (two injections at 20 mg/kg i.p., 30 min apart) reversed partially the nerve lesion-induced decrease in pressure threshold value to trigger vocalization in the Randall-Selitto test. As shown in figure 7A ,7C, this anti-hyperalgesic effect developed progressively in CCI-SN rats, up to a maximum 1-5 days after cyclotraxin B, which corresponded to half-recovery of healthy control mechanical sensitivity (C on abscissa). Thereafter, the effect of cyclotraxin B decreased progressively and was no longer significant on day 10 post-injection ( Fig. 7A) .
Similarly, cyclotraxin B increased the pressure threshold value to trigger vocalization in rats which had developed hyperalgesia 10 days after BDNF i.t. (Fig. 7B,7D) . At its maximum, on days 1-5 post-treatment, cyclotraxin B effect corresponded to half-reversal of BDNF i.t.induced hyperalgesia. Thereafter, this effect progressively vanished and hyperalgesia returned to pretreatment level on day 8 post-injection ( Fig. 7B) .
Neuroinflammation/glial activation markers in the spinal cord and dorsal root ganglia of CCI-SN-versus BDNF i.t.-rats
In CCI-SN rats, significant upregulation of transcripts encoding the neuronal injury marker ATF3 and the microglia activation markers OX-42 and Iba1 was observed in both the ipsilateral dorsal quadrant of the lumbar enlargement of the spinal cord (x 8.57, P < 0.01; x 2.56, P < 0.001; x 1.47, P<0.01, respectively) and ipsilateral L4-L6 DRG (x 16.33, P < 0.001; x 1.76, P < 0.05; x 1.62, P < 0.05, respectively) two weeks after surgery (Fig. 8) . In contrast, one day (not shown) as well as 10 days (Fig. 8 ) post-injection, when hyperalgesia and allodynia had reached their maximal intensities (see Fig. 1B,1D ), no changes in spinal cord and DRG levels of mRNAs encoding ATF3, OX-42 and Iba1 were detected in BDNF i.t. rats.
Data in figure 8 also show that CCI-SN induced significant upregulation of mRNAs encoding IL-6, BDNF and the NR2B subunit of NMDA receptors in both the ipsilateral dorsal quadrant of the lumbar enlargement of the spinal cord (x 3.68, P < 0.001; x 1.62, P < 0.05; x 1.44, P < 0.05, respectively) and L4-L6 DRG (x 15.43, P < 0.001; x 1.66, P < 0.05; x 1.67, P < 0.05, respectively) ( Fig. 8 ). BDNF mRNA upregulation was also observed in the dorsal half of the lumbar enlargement (x 1.42, P < 0.01), but not in L4-L6 DRG, of rats with hyperalgesia/allodynia on day 10 post BDNF i.t. (Fig. 8) . In contrast, neither IL-6 mRNA nor NR2B mRNA at spinal and DRG levels were significantly changed in BDNF i.t. rats (Fig. 8) , and GFAP mRNA remained unaffected by CCI-SN or BDNF i.t. under our experimental conditions ( Fig.8, and data not shown). III-V: +145.2 ± 11.6 %, P < 0.001) (Fig. 9A) . In contrast, no significant change in P-p38
Immunohistochemical labeling of P-p38 at spinal level in CCI
immunostaining was detected within the dorsal horn of the lumbar enlargement in BDNF i.t. rats (Fig. 9B ). However, stroking stimulation of the right hindpaw under conditions that did not affect P-p38 immunolabeling in control (saline i.t.) rats did produce significant increases in the density of P-p38 immunoreactive cells within both the superficial laminae I-II and deep laminae III-V of the ipsilateral dorsal horn in BDNF i.t. rats (Fig. 9B ).
Discussion
Our data showed that spinal administration of BDNF triggered sustained hyperalgesia-and allodynia-like behaviors in naïve healthy rats to the same extent as CCI-SN, further supporting the idea that this neurotrophin plays a cardinal role in physiopathological mechanisms underlying neuropathic pain . Of all the transcripts investigated in our studies, only the one encoding BDNF (exon IX) was found to be upregulated within the dorsal horn of BDNF i.t. rats, in line with previous data
showing that this neurotrophic factor can promote its own synthesis (Cheng et al., 2011; Zheng et al., 2012) . Such autocrine action of BDNF very probably explains why a single i.t.
administration of this neurotrophin produced a long-lasting TrkB-mediated neuropathic pain-like effect. Whether similar BDNF autocrine effect also underlay the maintenance of CCI-SN-induced neuropathic pain will have to be assessed by comparing the effects of cyclotraxin B on the expression of genes downstream of TrkB activation in both CCI-SN and BDNF-it rats.
In further support to the existence of close homology between the effects of BDNF i.t. and CCI-SN, drugs used to treat neuropathic pain in humans such as pregabalin, tapentadol and morphine (Finnerup et al., 2015) were found to be equally effective to reduce hyperalgesia in both models. In contrast, amitriptyline, duloxetine and clonazepam were equally ineffective under the acute treatment conditions used in our studies, in line with convergent data showing that these drugs, especially antidepressants, have to be administered chronically to exert significant anti-hyperalgesic effects (Benbouzid et al., 2008) . However, this was not the case with agomelatine since acute administration of this antidepressant significantly reduced hyperalgesia in both models. Agomelatine is an agonist at melatonergic MT1 and MT2 receptors and an antagonist at 5-HT 2B and 5-HT 2C receptors (de Bodinat et al., 2010) , which are all relevant targets for neuropathic pain alleviation (Ambriz-Tututi et al., 2009; Viguier et al., 2013) . Accordingly, concomitant actions at these receptors might account for its unique antihyperalgesic efficacy when compared to other antidepressants under acute treatment conditions. Interestingly, agomelatine was found to enhance BDNF expression in the rat hippocampus (Soumier et al., 2009) , and it would therefore be of interest to assess its effect on BDNF expression and TrkB activity at the spinal level.
Interestingly, the NMDA receptor antagonist ketamine was also found to inhibit both CCI-SNand BDNF i.t.-induced hyperalgesia, as expected from convergent data showing that BDNFinduced synaptic sensitization is mediated through facilitation of NMDA receptor-dependent glutamatergic nociceptive pathways (Geng et al., 2010; Chen et al., 2014) . As mRNA encoding the NR2B subunit of NMDA receptors was not upregulated 10 days after BDNF i.t.
injection, when hyperalgesia had fully developed, it can be inferred that BDNF did not induce NR2B transcription but most probably promoted its activation via phosphorylation, as previously reported in cortical and hippocampal neurons (Lin et al., 1998) .
In addition to promoting NMDA receptor-mediated neurotransmission, BDNF is known to downregulate the expression and activity of the KCC2 K + /Clco-transporter, which reduces the hyperpolarizing/inhibitory properties of GABA (Coull et al., 2005) . Whether this mechanism also contributes to BDNF i.t.-induced hyperalgesia/allodynia is an interesting possibility to be addressed in future investigations.
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